(Q37371309)

20 August 2017

1 reference

title

Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer (English)

1 reference

20 August 2017

1 reference

1 reference

A U Buzdar

1

1 reference

PubMed ID

19150946

20 August 2017

language of work or name

1 reference

15 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

20

1 reference

20 August 2017

6

1 reference

20 August 2017

993-999

1 reference

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer

20 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Advances in adjuvant hormonal therapy for postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN739

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN739

1 reference

20 August 2017

1 reference

PubMed ID

19150946